{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:10:39Z","timestamp":1753891839709,"version":"3.41.2"},"reference-count":13,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Intravascular large B-cell lymphoma (IVLBCL) is a rare, aggressive, large B-cell non-Hodgkin\u2019s lymphoma. The prognosis of IVLBCL in patients with central nervous system recurrence after first-line chemotherapy treatment is extremely poor. Among immunotherapies, chimeric antigen receptor (CAR) T-cell immunotherapy has been recently found to be a highly effective treatment for B-cell lymphoma, especially for relapsed or refractory diffuse large B-cell lymphoma. However, no guidelines are available that provide a clear consensus regarding the management of patients with relapsed\/refractory IVLBCL. Here, we report, for the first time, the use of autologous hematopoietic stem cell transplantation (ASCT) and CAR T-cell therapy in a patient with relapsed\/refractory IVLBCL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>A 42\u2010year\u2010old woman was diagnosed with IVLBCL based on liver biopsy and developed central nervous system (CNS) progression. The patient received ASCT combined with murine monoclonal anti-CD19 and anti-CD22 CAR T-cell therapy. She achieved complete remission for 22 months so far with negative minimal residual disease and continues to be followed up.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>ASCT combined with CAR T-cell therapy was the best choice for treatment of relapsed\/refractory IVLBCL, as it allowed the achievement of a lasting complete remission.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.817969","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T08:37:03Z","timestamp":1651135023000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Sequential CAR T-Cell Therapy After Autologous Stem Cell Transplantation for the Treatment of Relapsed\/Refractory Intravascular Large B-Cell Lymphoma With Central Nervous System Involvement: A Case Report"],"prefix":"10.3389","volume":"12","author":[{"given":"Wanying","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunrui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinhuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yicheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2020.04.005","article-title":"Intravascular Large B-Cell Lymphoma: A Case Series and Review of Literatures","volume":"44","author":"Ong","year":"2021","journal-title":"BioMed J"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4278","article-title":"Retrospective Analysis of Intravascular Large B-Cell Lymphoma Treated With Rituximab-Containing Chemotherapy as Reported by the IVL Study Group in Japan","volume":"26","author":"Shimada","year":"2008","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S267825","article-title":"Prognosis of Intravascular Large B Cell Lymphoma (IVLBCL): Analysis of 182 Patients From Global Case Series","volume":"12","author":"Liu","year":"2020","journal-title":"Cancer Manag Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01555.x","article-title":"Central Nervous System Involvement in Intravascular Large B-Cell Lymphoma: A Retrospective Analysis of 109 Patients","volume":"101","author":"Shimada","year":"2010","journal-title":"Cancer Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2018.396","article-title":"Asian Variant of Intravascular Large B-Cell Lymphoma: A Comparison of Clinical Features Based on Involvement of the Central Nervous System","volume":"35","author":"Yoon","year":"2020","journal-title":"Korean J Intern Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S1470-2045(20)30059-0","article-title":"Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Combined With High-Dose Methotrexate Plus Intrathecal Chemotherapy for Newly Diagnosed Intravascular Large B-Cell Lymphoma (PRIMEUR-IVL): A Multicentre, Single-Arm, Phase 2 Trial","volume":"21","author":"Shimada","year":"2020","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.339","article-title":"Autologous Hematopoietic Stem Cell Transplantation for Intravascular Large B-Cell Lymphoma: The European Society for Blood and Marrow Transplantation Experience","volume":"52","author":"Meissner","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and Safety of CAR19\/22 T-Cell Cocktail Therapy in Patients With Refractory\/Relapsed B-Cell Malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.08.012","article-title":"CD19\/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy Following Autologous Transplantation in Patients With Relapsed\/Refractory Aggressive B Cell Lymphomas","volume":"27","author":"Cao","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1172\/JCI30414","article-title":"Hematopoietic Stem Cells Promote the Expansion and Function of Adoptively Transferred Antitumor CD8+ T Cells","volume":"117","author":"Wrzesinski","year":"2007","journal-title":"J Clin Invest"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4441","article-title":"CD22-Targeted CAR T Cells Induce Remission in B-ALL That Is Naive or Resistant to CD19-Targeted CAR Immunotherapy","volume":"24","author":"Fry","year":"2018","journal-title":"Nat Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s13045-017-0516-x","article-title":"Novel Immunotherapies for Adult Patients With B-Lineage Acute Lymphoblastic Leukemia","volume":"10","author":"Wei","year":"2017","journal-title":"J Hematol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.817969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T08:37:05Z","timestamp":1651135025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.817969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":13,"alternative-id":["10.3389\/fonc.2022.817969"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.817969","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"article-number":"817969"}}